Ontorpacept

also known as TTI-621

Developed for: ALK-positive large B-cell lymphoma · B-cell lymphoma, unclassifiable, with features intermediate between diffuse large b-cell lymphoma and classical Hodgkin lymphoma · diffuse large B-cell lymphoma with chronic inflammation · high grade B-cell lymphoma · high grade B-cell lymphoma with MYC and/ or BCL2 and/or BCL6 rearrangement · intravascular large B-cell lymphoma · leiomyosarcoma · primary cutaneous diffuse large B-cell lymphoma, Leg type
+2 more
· primary mediastinal large B-cell lymphoma · T-cell/histiocyte rich large B cell lymphoma
Investigated by: Mayo Clinic · Pfizer

today NCT05507541 · Ph 2 NCT04996004 · Ph 2

202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 2	NCT05507541	Apr 2023 → Jul 2027 expected	ALK-positive large B-cell lymphoma, B-cell lymphoma, unclassifiable, with features intermediate between diffuse large b-cell lymphoma and classical Hodgkin lymphoma, T-cell/histiocyte rich large B cell lymphoma, diffuse large B-cell lymphoma with chronic inflammation +5	Mayo Clinic	Active not recruiting	No outcome recorded
Phase 2	NCT04996004	Jun 2021 → Dec 2023	leiomyosarcoma	Pfizer	Terminated	No outcome recorded

Every value below carries the sentence it was read from. 2 sources stand behind the page.

Field	Value	Cited text
Known as	Ontorpacept	ClinicalTrials.gov intervention name — accepted as the source's own label NCT05507541 ↗ 1 NCT04996004 ↗
Known as	TTI-621	“Ontorpacept (TTI-621) will be administered by intravenous infusion.” NCT04996004 ↗
Modality	Protein / enzyme biologic	“Ontorpacept / SIRPα-IgG1 Fc” NCT04996004 ↗
Route	Intravenous	“Ontorpacept (TTI-621) will be administered by intravenous infusion.” NCT04996004 ↗